Chen X, Chen F, Ren Y, Weng G, Xu L, Xue X, et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. J Cancer Res Clin Oncol. 2019;145:1471-1484 pubmed publisher

Helmy M, Helmy M, El Mas M. Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs. PLoS ONE. 2015;10:e0142303 pubmed publisher

Grzasko N, Chocholska S, Goracy A, Hus M, Dmoszynska A. Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor. Pharmacol Rep. 2015;67:1193-200 pubmed publisher

Liu Y, Huang X, He X, Zhou Y, Jiang X, Chen Kiang S, et al. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. FASEB J. 2015;29:4829-39 pubmed publisher

Li D, Zhang X, Jiang X, Yin Y, Fan Z, Sun C, et al. Protective effects of thalidomide on pulmonary injuries in a rat model of paraquat intoxication. J Inflamm (Lond). 2015;12:46 pubmed publisher

Lazzerini M, Martelossi S, Magazzu G, Pellegrino S, Lucanto M, Barabino A, et al. Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial. Inflamm Bowel Dis. 2015;21:1739-49 pubmed publisher

Chen L, Yang J, Zheng M, Kong X, Huang T, Cai Y. The Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung Cancer. PLoS ONE. 2015;10:e0128696 pubmed publisher

Xing J, Toh Y, Xu S, Yu H. A method for human teratogen detection by geometrically confined cell differentiation and migration. Sci Rep. 2015;5:10038 pubmed publisher

Song T, Wang L, Gu K, Yang Y, Yang L, Ma P, et al. Involvement of peripheral TRPV1 channels in the analgesic effects of thalidomide. Neurochem Int. 2015;85-86:40-5 pubmed publisher

Lee H, Kwon H, Park D, Woo Y, Kim H, Kim H, et al. Thalidomide inhibits alternative activation of macrophages in vivo and in vitro: a potential mechanism of anti-asthmatic effect of thalidomide. PLoS ONE. 2015;10:e0123094 pubmed publisher

Jacques V, Czarnik A, Judge T, Van der Ploeg L, DeWitt S. Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs. Proc Natl Acad Sci U S A. 2015;112:E1471-9 pubmed publisher

Matsuda T, Murao N, Katano Y, Juliandi B, Kohyama J, Akira S, et al. TLR9 signalling in microglia attenuates seizure-induced aberrant neurogenesis in the adult hippocampus. Nat Commun. 2015;6:6514 pubmed publisher

Lee J, Kim C, Kim S, Sethi G, Ahn K. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway. Cancer Lett. 2015;360:280-93 pubmed publisher

Astarita G, Avanesian A, Grimaldi B, Realini N, Justinova Z, Panlilio L, et al. Methamphetamine accelerates cellular senescence through stimulation of de novo ceramide biosynthesis. PLoS ONE. 2015;10:e0116961 pubmed publisher

Handa H, Saitoh T, Murakami H. [Immunomodulatory effects of lenalidomide]. Nihon Rinsho. 2015;73:156-61 pubmed

Ogura T. [Thalidomide, cereblon and multiple myeloma]. Nihon Rinsho. 2015;73:149-55 pubmed

Ito T, Ando H, Handa H. [Thalidomide teratogenicity and its direct target identification]. Nihon Rinsho. 2015;73:143-8 pubmed

Takeda Y, Sakaida E, Nakaseko C. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy]. Nihon Rinsho. 2015;73:130-6 pubmed

Kübra ElçioÄŸlu H, Kabasakal L, Tufan F, ElçioÄŸlu Ã, Solakoglu S, Kotil T, et al. Effects of systemic Thalidomide and intracerebroventricular Etanercept and Infliximab administration in a Streptozotocin induced dementia model in rats. Acta Histochem. 2015;117:176-81 pubmed publisher

Gerich M, Yoon J, Targan S, Ippoliti A, Vasiliauskas E. Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther. 2015;41:429-37 pubmed publisher

Stewart A, Rajkumar S, Dimopoulos M, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142-52 pubmed publisher

Amirshahrokhi K, Khalili A. The effect of thalidomide on ethanol-induced gastric mucosal damage in mice: involvement of inflammatory cytokines and nitric oxide. Chem Biol Interact. 2015;225:63-9 pubmed publisher

Kumar S, Berdeja J, Niesvizky R, Lonial S, Laubach J, Hamadani M, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15:1503-12 pubmed publisher

Rishi R, Ringwala S, Tracy J, Fatteh S. Prurigo nodularis and Hashimoto thyroiditis. Ann Allergy Asthma Immunol. 2014;113:673-4 pubmed publisher

Nakamitsu P, Compri C, de Fraia Pinto L, Gotardo Ã, de Oliveira C, Ribeiro M, et al. Thalidomide controls adipose tissue inflammation associated with high-fat diet-induced obesity in mice. Endocr Metab Immune Disord Drug Targets. 2015;15:151-8 pubmed

Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten M, Vellenga E, et al. Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2015;125:449-56 pubmed publisher

Zhu Y, Yin H, Bruins L, Shi C, Jedlowski P, Aziz M, et al. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. Blood. 2015;125:483-91 pubmed publisher

Sigler J. Drug updates and approvals: 2014 in review. Nurse Pract. 2014;39:14-23; quiz 23-4 pubmed publisher

Shan Y, Qi C, Zhao J, Liu Y, Gao H, Zhao D, et al. Higher frequency of peripheral blood follicular regulatory T cells in patients with new onset ankylosing spondylitis. Clin Exp Pharmacol Physiol. 2015;42:154-61 pubmed publisher

Li Y, Fu S, Chen H, Feng Q, Gao Y, Xue H, et al. Inhibition of endothelial Slit2/Robo1 signaling by thalidomide restrains angiogenesis by blocking the PI3K/Akt pathway. Dig Dis Sci. 2014;59:2958-66 pubmed publisher

Feingold K, Moser A, Shigenaga J, Grunfeld C. Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages. J Lipid Res. 2014;55:2501-8 pubmed publisher

Kovacs M, Davies G, Chapman J, Bahlis N, Voralia M, Roy J, et al. Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. Br J Haematol. 2015;168:511-7 pubmed publisher

Krause A, Märker Hermann E. [Spondyloarthritis including psoriatic arthritis]. Dtsch Med Wochenschr. 2014;139:2017-9 pubmed publisher

. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015;17:266-73 pubmed publisher

Vincent Rajkumar S. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:999-1009 pubmed publisher

Beltran B, Maza I, Moisés Alfaro C, Vásquez L, Quinones P, Morales D, et al. Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru. Am J Hematol. 2014;89:1160-1 pubmed publisher

Avigan D, Rosenblatt J. Current treatment for multiple myeloma. N Engl J Med. 2014;371:961-2 pubmed publisher

Benboubker L, Dimopoulos M, Dispenzieri A, Catalano J, Belch A, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906-17 pubmed publisher

Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci M, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895-905 pubmed publisher

Kater A, Tonino S, Egle A, Ramsay A. How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. Blood. 2014;124:2184-9 pubmed publisher

Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci M, Pezzi A, et al. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Am J Hematol. 2014;89:1085-91 pubmed publisher

Usmani S, Zhang Q, Stratton K, Qu P, Yaccoby S, Hansen E, et al. Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma. Leukemia. 2014;28:2413-5 pubmed publisher

Reece D, Masih Khan E, Atenafu E, Jimenez Zepeda V, Anglin P, Chen C, et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. Br J Haematol. 2015;168:46-54 pubmed publisher

Nowakowski G, Laplant B, Macon W, Reeder C, Foran J, Nelson G, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33:251-7 pubmed publisher

Popat R, Khan I, Dickson J, Cheesman S, Smith D, D Sa S, et al. An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma. Br J Haematol. 2015;168:148-51 pubmed publisher

Muchtar E, Ram R, Raanani P, Yeshurun M, Oniashvili N, Shpilberg O, et al. First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience. Leuk Res. 2014;38:1401-6 pubmed publisher

Hsieh M, Chau L, Hon Y. Single-step approach for fabrication of vancomycin-bonded silica monolith as chiral stationary phase. J Chromatogr A. 2014;1358:208-16 pubmed publisher

Joao C, Coelho I, Costa C, Esteves S, Lucio P. Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center. Ann Hematol. 2015;94:97-105 pubmed publisher

Venner C, Gillmore J, Sachchithanantham S, Mahmood S, Lane T, Foard D, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia. 2014;28:2304-10 pubmed publisher

Jian W, Levitt J, Lerner S, Sonpavde G. The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014;34:3383-9 pubmed

Zago M, Oehrlein K, Rendl C, Hahn Ast C, Kanz L, Weisel K. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. Ann Hematol. 2014;93:1993-9 pubmed publisher

Yang M, Chiao M, Lee H, Chen C, Yang Y, Shen C, et al. An innovative three-dimensional gelatin foam culture system for improved study of glioblastoma stem cell behavior. J Biomed Mater Res B Appl Biomater. 2015;103:618-28 pubmed publisher

Veluswamy R, Ward S, Yum K, Abramovitz R, Isola L, Jagannath S, et al. Adverse drug reaction: pomalidomide-induced liver injury. Lancet. 2014;383:2125-6 pubmed publisher

Droitcourt C, Rybojad M, Porcher R, Juillard C, Cosnes A, Joly P, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest. 2014;146:1046-1054 pubmed publisher

Scharpfenecker M, Floot B, Russell N, Coppes R, Stewart F. Thalidomide ameliorates inflammation and vascular injury but aggravates tubular damage in the irradiated mouse kidney. Int J Radiat Oncol Biol Phys. 2014;89:599-606 pubmed publisher

Oldziej A, Bolkun L, Galar M, Kalita J, Ostrowska H, Romaniuk W, et al. Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma. Leuk Res. 2014;38:925-30 pubmed publisher

Huang Y, Zang Y, Zhou L, Gui W, Liu X, Zhong Y. The role of TNF-alpha/NF-kappa B pathway on the up-regulation of voltage-gated sodium channel Nav1.7 in DRG neurons of rats with diabetic neuropathy. Neurochem Int. 2014;75:112-9 pubmed publisher

Bianchi G, Richardson P, Anderson K. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014;32:2125-32 pubmed publisher

James D, Werner L, Brown J, Wierda W, Barrientos J, Castro J, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014;32:2067-73 pubmed publisher

El Aarag B, Kasai T, Zahran M, Zakhary N, Shigehiro T, Sekhar S, et al. In vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs. Int Immunopharmacol. 2014;21:283-92 pubmed publisher

Sanfilippo K, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R, et al. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. Leuk Lymphoma. 2015;56:615-21 pubmed publisher

Li Y, Zhou S, Hoffmann M, Kumar G, Palmisano M. Modeling and simulation to probe the pharmacokinetic disposition of pomalidomide R- and S-enantiomers. J Pharmacol Exp Ther. 2014;350:265-72 pubmed publisher

Lee M, Wickner P, Fanning L, Schlossman R, Richardson P, Laubach J, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167:127-31 pubmed publisher

Buckstein R, Kerbel R, Cheung M, Shaked Y, Chodirker L, Lee C, et al. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. Leuk Res. 2014;38:756-63 pubmed publisher

Govindaraj C, Madondo M, Kong Y, Tan P, Wei A, Plebanski M. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Am J Hematol. 2014;89:795-802 pubmed publisher

Baret I, De Haes P. Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?. J Dermatolog Treat. 2015;26:173-7 pubmed publisher

Ahn S, Jung S, Joo Y, Lee W, Lee S, Choi C, et al. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. Ann Hematol. 2014;93:1571-7 pubmed publisher

Zelis N, deVos T, Dierickx D, Janssens A, Raddoux J, Verhoef G, et al. Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study. Acta Clin Belg. 2014;69:98-103 pubmed publisher

Ghosh N, Tucker N, Zahurak M, Wozney J, Borrello I, Huff C. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. Am J Hematol. 2014;89:E116-20 pubmed publisher

Moros A, Rodriguez V, Saborit Villarroya I, Montraveta A, Balsas P, Sandy P, et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia. 2014;28:2049-59 pubmed publisher

Sanchez Garcia J, del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, et al. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. Br J Haematol. 2014;166:189-201 pubmed publisher

Schuelper N, Flohr A, Trumper L, Wulf G. Osteolytic lesions in patients with relapse of diffuse large B-cell lymphoma treated with lenalidomide. Ann Hematol. 2014;93:1929-30 pubmed publisher

Milanović D, Maier P, Schanne D, Wenz F, Herskind C. The influence of retinoic Acid and thalidomide on the radiosensitivity of u343 glioblastoma cells. Anticancer Res. 2014;34:1885-91 pubmed

Mark T, Coleman M, Niesvizky R. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. Leuk Res. 2014;38:517-24 pubmed publisher

Huang S, Lin C, Lin H, Yao M, Tang J, Wu S, et al. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol. 2014;93:1371-80 pubmed publisher

deVos T, Thiessen S, Cuyle P, Meersseman W, Delforge M. Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years. Ann Hematol. 2014;93:1927-8 pubmed publisher

Feldman T, Mato A, Chow K, Protomastro E, Yannotti K, Bhattacharyya P, et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol. 2014;166:77-83 pubmed publisher

Gaballa M, Besa E. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Ann Hematol. 2014;93:723-33 pubmed publisher

Chen C, Paul H, Wang T, Le L, Dave N, Kukreti V, et al. Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. Br J Haematol. 2014;165:731-3 pubmed publisher

Okur A, Eser E, Yilmaz G, Dalgic A, Akdemir U, Oguz A, et al. Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. J Pediatr Hematol Oncol. 2014;36:e328-32 pubmed publisher

Yang C, Qureshi A, Churchill W, Saavedra A. Long-term plasmapheresis in conjunction with thalidomide and dexamethasone for the treatment of cutaneous ulcers and neovascular glaucoma in recalcitrant type I cryoglobulinemia. JAMA Dermatol. 2014;150:426-8 pubmed publisher

Zhang M, Qian J, Lan Y, Lu Y, Li H, Hong B, et al. Anti-??M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity. Int J Cancer. 2014;135:1132-41 pubmed publisher

Vargesson N, Mahony C, Erskine L, Niven J, Greig N, Figg W. Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. Proc Natl Acad Sci U S A. 2013;110:E4820 pubmed

Visani G, Ferrara F, Di Raimondo F, Loscocco F, Sparaventi G, Paolini S, et al. Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients. Leukemia. 2014;28:967-70 pubmed publisher

Stewart A. Medicine. How thalidomide works against cancer. Science. 2014;343:256-7 pubmed publisher

Landgren O, Mailankody S. Update on second primary malignancies in multiple myeloma: a focused review. Leukemia. 2014;28:1423-6 pubmed publisher

Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, et al. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014;93:541-56 pubmed publisher

Szturz P, Adam Z, Rehák Z, Koukalová R, Kren L, Moulis M, et al. Salvage lenalidomide in four rare oncological diseases. Tumori. 2013;99:e251-6 pubmed publisher

Panousis K, Nikolaou V, Tsaganos T, Lallos S, Giamarellos Bourboulis E, Efstathopoulos N. Thalidomide prolongs survival after experimental musculoskeletal injury, through an effect on mononuclear apoptosis. J Surg Res. 2014;188:198-205 pubmed publisher

Ingen Housz Oro S, Ortonne N, Chosidow O. IgG4-related skin disease--reply. JAMA Dermatol. 2013;149:1440 pubmed publisher

Lehman J, Pittelkow M, Smyrk T. IgG4-related skin disease. JAMA Dermatol. 2013;149:1439-40 pubmed publisher

Yamada M, Kuroda H, Jomen W, Yoshida M, Miura S, Abe T, et al. [A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts]. Gan To Kagaku Ryoho. 2013;40:2593-7 pubmed

Takamatsu H, Munemoto S, Murata R, Terasaki Y, Nakajima K, Nakao S. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma. Anticancer Res. 2013;33:5681-5 pubmed

D Amato R, Lentzsch S, Rogers M. Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models. Proc Natl Acad Sci U S A. 2013;110:E4818 pubmed publisher

Zeldis J, Carter T, Knight R, Hui J. Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans. Proc Natl Acad Sci U S A. 2013;110:E4819 pubmed publisher

Krönke J, Udeshi N, Narla A, Grauman P, Hurst S, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301-5 pubmed publisher

Lu G, Middleton R, Sun H, Naniong M, Ott C, Mitsiades C, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305-9 pubmed publisher

Lazzerini M, Martelossi S, Magazzu G, Pellegrino S, Lucanto M, Barabino A, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA. 2013;310:2164-73 pubmed publisher

Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, et al. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. Am J Hematol. 2014;89:355-62 pubmed publisher

Lazaryan A, Hussein M, Reu F, Faiman B, Habecker B, Ann Karam M, et al. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. Am J Hematol. 2014;89:349-54 pubmed publisher

Feng Q, Tan H, Ge Z, Gao Y, Chen H, Xiao S. Thalidomide-induced angiopoietin 2, Notch1 and Dll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells. J Dig Dis. 2014;15:85-95 pubmed publisher

Tovar N, Fernández de Larrea C, Pedrosa F, Arostegui J, Cibeira M, Rosinol L, et al. Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. Ann Hematol. 2014;93:107-11 pubmed publisher

Prince S, Forgeson G. Bleeding from gastrointestinal tract recurrence of non-seminomatous germ cell tumour testis, showing temporary response to gemcitabine and oxaliplatin chemotherapy. N Z Med J. 2013;126:76-80 pubmed

Gandhi A, Mendy D, Waldman M, Chen G, Rychak E, Miller K, et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014;164:233-44 pubmed publisher

Tsuda K, Tanimoto T, Komatsu T. Treatment for high-risk smoldering myeloma. N Engl J Med. 2013;369:1763 pubmed publisher

Kristinsson S, Holmberg E, Blimark C. Treatment for high-risk smoldering myeloma. N Engl J Med. 2013;369:1762-3 pubmed publisher

Mateos M, San Miguel J. Treatment for high-risk smoldering myeloma. N Engl J Med. 2013;369:1764-5 pubmed publisher

Imanishi S, Okura M, Zaha H, Yamamoto T, Akanuma H, Nagano R, et al. Prenatal exposure to permethrin influences vascular development of fetal brain and adult behavior in mice offspring. Environ Toxicol. 2013;28:617-29 pubmed publisher

Lonial S. "A fortuitous combination of circumstances". Blood. 2013;122:2768-9 pubmed publisher

Orlowski R. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol. 2013;40:634-51 pubmed publisher

Mateos M, Ocio E, San Miguel J. Novel generation of agents with proven clinical activity in multiple myeloma. Semin Oncol. 2013;40:618-33 pubmed publisher

Cavo M, Brioli A, Tacchetti P, Zannetti B, Mancuso K, Zamagni E. Role of consolidation therapy in transplant eligible multiple myeloma patients. Semin Oncol. 2013;40:610-7 pubmed publisher

Robison N, Campigotto F, Chi S, Manley P, Turner C, Zimmerman M, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014;61:636-42 pubmed publisher

Lee S, Yoon J, Shin S, Cho B, Eom K, Kim Y, et al. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma. Ann Hematol. 2014;93:627-34 pubmed publisher

Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, Eleutherakis Papaiakovou E, et al. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia. 2014;28:928-34 pubmed publisher

Safran H, Charpentier K, Kaubisch A, Mantripragada K, Dubel G, Perez K, et al. Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study. Am J Clin Oncol. 2015;38:1-4 pubmed publisher

He P, Cheng X, Staufenbiel M, Li R, Shen Y. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of ?-secretase in a mouse model of Alzheimer's disease. PLoS ONE. 2013;8:e55091 pubmed publisher

Yamamoto M, Matsuzaki T, Takahashi R, Adachi E, Maeda Y, Yamaguchi S, et al. The transformation suppressor gene Reck is required for postaxial patterning in mouse forelimbs. Biol Open. 2012;1:458-66 pubmed publisher

Hernández P, Cabrera M, Lavaggi M, Celano L, Tiscornia I, Rodrigues da Costa T, et al. Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorg Med Chem. 2012;20:2158-71 pubmed publisher

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7:e1002310 pubmed publisher

Huo A, Zhang H, Guan Y, Zeng G, Chen Y, Li X. Stable and orally bio-available pro-drugs of CPS11. Bioorg Med Chem Lett. 2011;21:6242-4 pubmed publisher

da Silva Y, Augusto C, de Castro Barbosa M, de Albuquerque Melo G, de Queiroz A, de Lima Matos Freire Dias T, et al. Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorg Med Chem. 2010;18:5007-15 pubmed publisher

Mayshar Y, Yanuka O, Benvenisty N. Teratogen screening using transcriptome profiling of differentiating human embryonic stem cells. J Cell Mol Med. 2011;15:1393-401 pubmed publisher

Stewart S, Braun C, Ng S, Polomska M, Karimi M, Abraham L. New thalidomide analogues derived through Sonogashira or Suzuki reactions and their TNF expression inhibition profiles. Bioorg Med Chem. 2010;18:650-62 pubmed publisher

Kruhlak N, Choi S, Contrera J, Weaver J, Willard J, Hastings K, et al. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicol Mech Methods. 2008;18:217-27 pubmed publisher

Fourches D, Barnes J, Day N, Bradley P, Reed J, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol. 2010;23:171-83 pubmed publisher

Vincent F, Nguyen M, Emerling D, Kelly M, Duncton M. Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors. Bioorg Med Chem Lett. 2009;19:6793-6 pubmed publisher

Fernández Braña M, Acero N, Añorbe L, Muñoz Mingarro D, Llinares F, Domínguez G. Discovering a new analogue of thalidomide which may be used as a potent modulator of TNF-alpha production. Eur J Med Chem. 2009;44:3533-42 pubmed publisher

Yamamoto T, Shibata N, Sukeguchi D, Takashima M, Nakamura S, Toru T, et al. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides. Bioorg Med Chem Lett. 2009;19:3973-6 pubmed publisher

Contino Pépin C, Parat A, Perino S, Lenoir C, Vidal M, Galons H, et al. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application. Bioorg Med Chem Lett. 2009;19:878-81 pubmed publisher

Zahran M, Salem T, Samaka R, Agwa H, Awad A. Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice. Bioorg Med Chem. 2008;16:9708-18 pubmed publisher

Huang S, Ho C, Lin C, Fang H, Peng Y. Development and biological evaluation of C(60) fulleropyrrolidine-thalidomide dyad as a new anti-inflammation agent. Bioorg Med Chem. 2008;16:8619-26 pubmed publisher

Kodimuthali A, Jabaris S, Pal M. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. J Med Chem. 2008;51:5471-89 pubmed publisher

Nakagawa A, Uno S, Makishima M, Miyachi H, Hashimoto Y. Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008;16:7046-54 pubmed publisher

Obach R, Lombardo F, Waters N. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36:1385-405 pubmed publisher

Stewart S, Spagnolo D, Polomska M, Sin M, Karimi M, Abraham L. Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cross coupling. Bioorg Med Chem Lett. 2007;17:5819-24 pubmed

de Blanco E, Pandit B, Hu Z, Shi J, Lewis A, Li P. Inhibitors of NF-kappaB derived from thalidomide. Bioorg Med Chem Lett. 2007;17:6031-5 pubmed

Diamandis P, Wildenhain J, Clarke I, Sacher A, Graham J, Bellows D, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol. 2007;3:268-73 pubmed

MacDonald M, Lamerdin J, Owens S, Keon B, Bilter G, Shang Z, et al. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006;2:329-37 pubmed

Noguchi T, Fujimoto H, Sano H, Miyajima A, Miyachi H, Hashimoto Y. Angiogenesis inhibitors derived from thalidomide. Bioorg Med Chem Lett. 2005;15:5509-13 pubmed

Noguchi T, Miyachi H, Katayama R, Naito M, Hashimoto Y. Cell differentiation inducers derived from thalidomide. Bioorg Med Chem Lett. 2005;15:3212-5 pubmed

Inatsuki S, Noguchi T, Miyachi H, Oda S, Iguchi T, Kizaki M, et al. Tubulin-polymerization inhibitors derived from thalidomide. Bioorg Med Chem Lett. 2005;15:321-5 pubmed

Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-71 pubmed

Makonkawkeyoon S, Limson Pobre R, Moreira A, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1993;90:5974-8 pubmed

D Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-5 pubmed